Cargando…
Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention
Hereditary retinal diseases are now the leading cause of blindness certification in the working age population (age 16–64 years) in England and Wales, of which retinitis pigmentosa (RP) is the most common disorder. RP may be complicated by cystoid macular oedema (CMO), causing a reduction of central...
Autores principales: | Strong, S, Liew, G, Michaelides, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256121/ https://www.ncbi.nlm.nih.gov/pubmed/27913439 http://dx.doi.org/10.1136/bjophthalmol-2016-309376 |
Ejemplares similares
-
Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa
por: Strong, Stacey A, et al.
Publicado: (2020) -
Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
por: Strong, Stacey A., et al.
Publicado: (2016) -
Acetazolamide for Cystoid Macular Oedema in Bietti Crystalline Retinal Dystrophy
por: Broadhead, Geoffrey K, et al.
Publicado: (2014) -
Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa
por: Kitahata, Shohei, et al.
Publicado: (2018) -
Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
por: Majumder, Parthopratim Dutta, et al.
Publicado: (2016)